Baillie Gifford & CO Crispr Therapeutics Ag Transaction History

Baillie Gifford & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$44.62 - $62.75 $1.81 Million - $2.55 Million	-40,657 Reduced 10.03%	364,768 $17.1 Million
Q2 2024 Jul 25, 2024	BUY	$51.17 - $68.18 $486,626 - $648,391	9,510 Added 2.4%	405,425 $21.9 Million
Q1 2024 May 01, 2024	SELL	$60.67 - $89.12 $1.63 Million - $2.39 Million	-26,848 Reduced 6.35%	395,915 $27 Million
Q4 2023 Jan 26, 2024	SELL	$38.62 - $72.18 $706,746 - $1.32 Million	-18,300 Reduced 4.15%	422,763 $26.5 Million
Q3 2023 Nov 13, 2023	BUY	$45.39 - $59.0 $8.96 Million - $11.7 Million	197,469 Added 81.06%	441,063 $20 Million
Q2 2023 Jul 28, 2023	SELL	$43.47 - $67.77 $858,836 - $1.34 Million	-19,757 Reduced 7.5%	243,594 $13.7 Million
Q4 2022 Jan 24, 2023	SELL	$39.19 - $65.67 $987,666 - $1.66 Million	-25,202 Reduced 8.73%	263,351 $10.7 Million
Q3 2022 Oct 27, 2022	BUY	$61.1 - $83.78 $17.6 Million - $24.2 Million	288,553 New	288,553 $18.9 Million

483

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.07B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.